Friday, July 10, 2026

pharma · Ulcerative Colitis · Diabetes Mellitus, Type 2

Eli Lilly and

Eli Lilly and is a pharma organization headquartered in GURGAON, CN. Primary therapeutic focus areas include Ulcerative Colitis, Diabetes Mellitus, Type 2, Breast Neoplasms, Non Small Cell Lung Cancer, Systemic Lupus Ery

Lilly Corporate Center, Indianapolis, Indiana 46285, US HQ
55,860 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Lilly Corporate Center, Indianapolis, Indiana 46285, US
Employees
55,860
Programs
62
Drugs
42
Patents
0
Clinical program

LY2127399

Phase 3 · small molecule · Rheumatoid Arthritis

LY2127399 for Rheumatoid Arthritis is a Phase 3 program (small_molecule) at Eli Lilly and Company with 1 ClinicalTrials.gov record(s).

← All Eli Lilly and Company projects Phase 3 small molecule terminated

Internal code 13732

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Eli Lilly and Company
Phase
Phase 3
Modality
small_molecule
Indication
Rheumatoid Arthritis
Status
terminated
Trials
1

Clinical trials